| P/E (FY) | — | Sales (TTM) | — |
| Earnings (TTM) | -CAD 10.0M | ROE | — |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
| Market Cap | $16.9M | Trading Days | 1833 |
| 52W High | 1.40 |
| 52W Low | 0.24 |
| % Off High | −82.71% |
| YTD | −64.21% | 1Y | −60.97% |
| 3Y | 36.72% | 5Y | −64.93% |
| 10Y | −97.31% | Since incept. (ann.) | −30.22% |
| Ann. Volatility (1Y) | 81.30% | Ann. Volatility (3Y) | 97.61% |
| Sharpe (1Y) | −0.76 | Sharpe (3Y) | 0.57 |
| Max Drawdown (1Y) | −79.83% | Max Drawdown (3Y) | −88.41% |
| Beta (3Y, vs SPY) | 1.60 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| LPCN | Lipocine Inc. | $17.1M | — |
| DARE | Dare Bioscience, Inc. | $17.4M | — |
| CDT | CDT Equity Inc. | $16.1M | — |
| NXTC | NextCure, Inc. | $18.1M | — |
| CTXR | Citius Pharmaceuticals, Inc. | $15.6M | — |
| ALLR | Allarity Therapeutics, Inc. | $18.5M | — |
| MRKR | Marker Therapeutics, Inc. | $18.5M | — |
| MDCX | Medicus Pharma Ltd. | $15.3M | — |
| CYCN | Cyclerion Therapeutics, Inc. | $15.2M | — |
| KTTA | Pasithea Therapeutics Corp. | $15.0M | — |
| SCNX | Scienture Holdings, Inc. | $14.9M |
| — |
| CELU | Celularity Inc | $19.4M | — |
